(Q36658955)

15 August 2017

1 reference

title

Anabolic skeletal therapy for osteoporosis (English)

1 reference

15 August 2017

0 references

3

John P Bilezikian

1 reference

15 August 2017

2

Mishaela R Rubin

1 reference

15 August 2017

Monica Girotra

1

1 reference

15 August 2017

1 August 2006

1 reference

Arquivos Brasileiros de Endocrinologia e Metabologia

15 August 2017

1 reference

15 August 2017

50

1 reference

15 August 2017

4

1 reference

15 August 2017

745-754

1 reference

Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use.

15 August 2017

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400019

The anabolic effects of parathyroid hormone therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400019

Recombinant Human Parathyroid Hormone (1–34) [Teriparatide] Improves Both Cortical and Cancellous Bone Structure

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400019

Intermittently administered human parathyroid hormone(1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400019

Parathyroid hormone and periosteal bone expansion

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400019

Risk of new vertebral fracture in the year following a fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400019

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400019

The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400019

The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400019

Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400019

Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400019

Daily and cyclic parathyroid hormone in women receiving alendronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400019

The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400019

The Effects of Parathyroid Hormone, Alendronate, or Both in Men with Osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400019

Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400019

Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400019

One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400019

Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400019

Teriparatide [human PTH(1-34)]: 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400019

Combination and sequential therapy for osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400019

Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400019

Mechanisms of action and therapeutic potential of strontium in bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400019

Is the calcium receptor a molecular target for the actions of strontium on bone?

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400019

A novel cation-sensing mechanism in osteoblasts is a molecular target for strontium

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400019

The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400019

Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400019

Effects of human growth hormone in men over 60 years old

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400019

Growth hormone rising: did we quit too quickly?

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400019

10.1590/S0004-27302006000400019

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference

PubMed ID

17117299